- Home
- COCP
as 11-26-2025 12:58pm EST
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 15.4M | IPO Year: | N/A |
| Target Price: | $6.00 | AVG Volume (30 days): | 82.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.90 - $3.26 | Next Earning Date: | 11-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Cocrystal Pharma Inc. (COCP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | COCP | Director, 10% Owner | Nov 25 '25 | Buy | $0.94 | 20,000 | $18,812.00 | 1,699,551 |
Latest Cocrystal Pharma Inc. News
COCP Breaking Stock News: Dive into COCP Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
10 days ago
COCP: Phase 1b Norovirus Challenge Study of CDI-988 to Commence in 1Q26…
GlobeNewswire
14 days ago
Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
GlobeNewswire
a month ago
Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules
GlobeNewswire
2 months ago
Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
GlobeNewswire
2 months ago
Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Associated Press Finance
3 months ago
BC-Most Active Stocks
MT Newswires
3 months ago
Cocrystal Pharma Reports Direct Offering; Shares Rise
GlobeNewswire
3 months ago
Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment
Compare COCP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COCP Cocrystal Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.